MX2009006007A - Profarmacos y metodos para hacer y usar los mismos. - Google Patents

Profarmacos y metodos para hacer y usar los mismos.

Info

Publication number
MX2009006007A
MX2009006007A MX2009006007A MX2009006007A MX2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A MX 2009006007 A MX2009006007 A MX 2009006007A
Authority
MX
Mexico
Prior art keywords
prodrugs
methods
parent drug
making
same
Prior art date
Application number
MX2009006007A
Other languages
English (en)
Spanish (es)
Inventor
Keith R Bley
Naweed Muhammad
Original Assignee
Neurogesx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogesx Inc filed Critical Neurogesx Inc
Publication of MX2009006007A publication Critical patent/MX2009006007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2009006007A 2006-12-05 2007-12-05 Profarmacos y metodos para hacer y usar los mismos. MX2009006007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87351906P 2006-12-05 2006-12-05
PCT/US2007/024984 WO2008070149A2 (en) 2006-12-05 2007-12-05 Prodrugs and methods of making and using the same

Publications (1)

Publication Number Publication Date
MX2009006007A true MX2009006007A (es) 2009-07-17

Family

ID=39361296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006007A MX2009006007A (es) 2006-12-05 2007-12-05 Profarmacos y metodos para hacer y usar los mismos.

Country Status (12)

Country Link
US (1) US20080318905A1 (enExample)
EP (1) EP2121029A2 (enExample)
JP (1) JP2010511717A (enExample)
KR (1) KR20090086627A (enExample)
CN (1) CN101678120A (enExample)
AU (1) AU2007328007A1 (enExample)
BR (1) BRPI0719937A2 (enExample)
CA (1) CA2671737A1 (enExample)
MX (1) MX2009006007A (enExample)
NO (1) NO20092527L (enExample)
RU (1) RU2009125597A (enExample)
WO (1) WO2008070149A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
CN101622263B (zh) * 2007-03-06 2013-05-29 卫材R&D管理有限公司 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
CA2724881C (en) 2008-05-20 2016-09-27 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
WO2009143299A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
CN105254662A (zh) 2008-05-20 2016-01-20 阿索尔达治疗公司 水溶性对乙酰氨基酚类似物
WO2010013158A1 (en) 2008-07-28 2010-02-04 Pfizer Inc. Phenanthrenone compounds, compositions and methods
US20100076198A1 (en) * 2008-09-19 2010-03-25 Mallinckrodt Inc. Crystalline forms of Fentanyl Alkaloid
NZ597108A (en) * 2009-06-25 2014-04-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds
SMT201700430T1 (it) 2009-06-25 2018-01-11 Alkermes Pharma Ireland Ltd Composti eterociclici per il trattamento di disturbi neurologici e psicologici
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
HUE032109T2 (en) 2011-03-18 2017-08-28 Alkermes Pharma Ireland Ltd Injectable pharmaceutical compositions containing water insoluble antipsychotic, sorbitan laurate and polysorbate 20
BR112014002084B1 (pt) * 2011-07-28 2022-03-29 Kempharm, Inc Composição de pró-fármaco e uso de conjugado de metilfenidato
US9024055B2 (en) 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
EP2827868B8 (en) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
WO2014172482A1 (en) 2013-04-17 2014-10-23 Robert Alfred Volkmann Compounds for treatment of pain
US10072018B2 (en) 2013-04-17 2018-09-11 Biopharma Works Compounds for treatment of pain
EP3004115B1 (en) 2013-05-24 2019-03-06 Rhodes Technologies Opioid ketal compounds and uses thereof
ES2784690T3 (es) 2013-12-05 2020-09-29 Univ Bath Nuevos compuestos opioides y sus usos
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN108135864A (zh) * 2015-05-13 2018-06-08 4P-制药公司 兴奋剂防滥用组合物
US20170273974A1 (en) * 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
WO2019086017A1 (en) * 2017-11-03 2019-05-09 Nirsum Laboratories, Inc. Opioid receptor antagonist prodrugs
US11845759B2 (en) 2018-02-23 2023-12-19 Rhodes Technologies Opioid compounds and uses thereof
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020077038A1 (en) * 2018-10-13 2020-04-16 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of cgrp antagonists
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
WO2020227337A1 (en) * 2019-05-07 2020-11-12 Bristol-Myers Squibb Company Prodrug compounds
FI130262B (en) * 2019-08-30 2023-05-17 Medicortex Finland Oy Formulations and compositions for use in the prevention or treatment of brain injury and neurodegenerative diseases
AU2020360928A1 (en) * 2019-09-30 2022-04-14 Nippon Chemiphar Co., Ltd. Azepan derivative
CN114380859B (zh) * 2020-10-22 2024-11-01 威智医药股份有限公司 磷酸二苄酯及焦磷酸四苄酯的制备方法
CN117805249A (zh) * 2022-09-23 2024-04-02 合肥瀚微生物科技有限公司 一种抑郁症诊断的生物标记物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
PT1685839E (pt) * 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
CA2317008C (en) * 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
ATE454169T1 (de) * 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
EP3326617A1 (en) * 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations

Also Published As

Publication number Publication date
RU2009125597A (ru) 2011-01-20
EP2121029A2 (en) 2009-11-25
JP2010511717A (ja) 2010-04-15
KR20090086627A (ko) 2009-08-13
WO2008070149A3 (en) 2009-12-10
NO20092527L (no) 2009-09-04
BRPI0719937A2 (pt) 2014-03-11
AU2007328007A1 (en) 2008-06-12
CN101678120A (zh) 2010-03-24
CA2671737A1 (en) 2008-06-12
US20080318905A1 (en) 2008-12-25
WO2008070149A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
EP2562177A3 (en) Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
TW200621730A (en) Chemical compounds
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
WO2008064192A3 (en) Modified release analgesic suspensions
GB2423928A (en) Methods and compositions for treating pain
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
EP2061456A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
GB2446341A (en) Method and system for transdermal drug delivery
WO2009045053A3 (en) A cancer sensitizer comprising chlorogenic acid
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
EA201270551A1 (ru) Лечение нейротоксичности, ассоциированной с комбинациями 5-fu или его пролекарств с ингибиторами dpd
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution

Legal Events

Date Code Title Description
FA Abandonment or withdrawal